Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.29 USD | -3.72% | -8.30% | +5.20% |
Financials (USD)
Sales 2024 * | 204K | Sales 2025 * | 11.85M | Capitalization | 185M |
---|---|---|---|---|---|
Net income 2024 * | -72M | Net income 2025 * | -62M | EV / Sales 2024 * | 907 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 15.6 x |
P/E ratio 2024 * |
-2.48
x | P/E ratio 2025 * |
-3.56
x | Employees | 24 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.36% |
Latest transcript on Outlook Therapeutics, Inc.
1 day | -3.72% | ||
1 week | -8.30% | ||
Current month | -30.57% | ||
1 month | +6.49% | ||
3 months | +16.01% | ||
6 months | -12.13% | ||
Current year | +5.20% |
Managers | Title | Age | Since |
---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 18-04-12 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 15-12-10 |
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +4.47% | - | |
0.00% | 147 M€ | +4.24% | - | |
0.00% | 18 M€ | +3.53% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 8.29 | -3.72% | 234,621 |
24-04-17 | 8.61 | -1.60% | 418,152 |
24-04-16 | 8.75 | +1.51% | 136,801 |
24-04-15 | 8.62 | -0.92% | 234,921 |
24-04-12 | 8.7 | -3.76% | 267,111 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.20% | 185M | |
-1.82% | 41.35B | |
+42.04% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- OTLK Stock